Literature DB >> 25483466

Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Evgeny Shmelkov1, Arthur Nadas, Timothy Cardozo.   

Abstract

The immune-correlate analysis of the RV144 clinical trial revealed that human plasma IgA immune responses elicited by the RV144 vaccine correlated positively with a risk for HIV acquisition. This result once again emphasized that HIV vaccines can potentially have adverse effects leading to enhancement of infection. Here, we discuss previously reported evidence of antibody-dependent enhancement of HIV infection. We also describe how a structure-based epitope-specific sieve-analysis can be employed to mine the molecular mechanism underlying this phenomenon.

Entities:  

Keywords:  HIV vaccine; HIV vaccine clinical trials; antibody; antibody epitopes; antibody-dependent enhancement of infection

Mesh：

Substances：

Year:  2014        PMID： 25483466      PMCID： PMC5443089          DOI： 10.4161/21645515.2014.972148

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  38 in total

1.  The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells.

Authors:  J Homsy; M Meyer; M Tateno; S Clarkson; J A Levy
Journal:  Science       Date:  1989-06-16       Impact factor: 47.728

2.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

3.  Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice.

Authors:  M J Wallace; D W Smith; A K Broom; J S Mackenzie; R A Hall; G R Shellam; P C McMinn
Journal:  J Gen Virol       Date:  2003-07       Impact factor: 3.891

4.  Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

Authors:  W E Robinson; D C Montefiori; W M Mitchell
Journal:  Lancet       Date:  1988-04-09       Impact factor: 79.321

Review 5.  Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

Authors:  D P Francis; T Gregory; M J McElrath; R B Belshe; G J Gorse; S Migasena; D Kitayaporn; P Pitisuttitham; T Matthews; D H Schwartz; P W Berman
Journal:  AIDS Res Hum Retroviruses       Date:  1998-10       Impact factor: 2.205

6.  Immunology. Immune activation with HIV vaccines.

Authors:  Anthony S Fauci; Mary A Marovich; Carl W Dieffenbach; Eric Hunter; Susan P Buchbinder
Journal:  Science       Date:  2014-04-04       Impact factor: 47.728

7.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Authors:  Morgane Rolland; Sodsai Tovanabutra; Allan C deCamp; Nicole Frahm; Peter B Gilbert; Eric Sanders-Buell; Laura Heath; Craig A Magaret; Meera Bose; Andrea Bradfield; Annemarie O'Sullivan; Jacqueline Crossler; Teresa Jones; Marty Nau; Kim Wong; Hong Zhao; Dana N Raugi; Stephanie Sorensen; Julia N Stoddard; Brandon S Maust; Wenjie Deng; John Hural; Sheri Dubey; Nelson L Michael; John Shiver; Lawrence Corey; Fusheng Li; Steve G Self; Jerome Kim; Susan Buchbinder; Danilo R Casimiro; Michael N Robertson; Ann Duerr; M Juliana McElrath; Francine E McCutchan; James I Mullins
Journal:  Nat Med       Date:  2011-02-27       Impact factor: 53.440

8.  Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes.

Authors:  James Swetnam; Evgeny Shmelkov; Susan Zolla-Pazner; Timothy Cardozo
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

9.  The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Authors:  Sandeep Gupta; Johannes S Gach; Juan C Becerra; Tran B Phan; Jeffrey Pudney; Zina Moldoveanu; Sarah B Joseph; Gary Landucci; Medalyn Jude Supnet; Li-Hua Ping; Davide Corti; Brian Moldt; Zdenek Hel; Antonio Lanzavecchia; Ruth M Ruprecht; Dennis R Burton; Jiri Mestecky; Deborah J Anderson; Donald N Forthal
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

Review 10.  Vaccine-induced enhancement of viral infections.

Authors:  W Huisman; B E E Martina; G F Rimmelzwaan; R A Gruters; A D M E Osterhaus
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641
View more
  4 in total

1.  Response to letter to the editor.

Authors:  Evgeny Shmelkov; Timothy Cardozo
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.

Authors:  Shannon R Roff; Missa P Sanou; Mobeen H Rathore; Jay A Levy; Janet K Yamamoto
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection.

Authors:  Sandhya Vasan; Supachai Rerks-Ngarm; Peter Gilbert; Barton Haynes; Sorachai Nitayapan; Punnee Pitisuttihum; Jaranit Kaewkungwal; Jean-Louis Excler; Merlin Robb; Nelson Michael; Jerome Kim; Robert O'Connell
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety.

Authors:  Ronald N Kostoff; Darja Kanduc; Alan L Porter; Yehuda Shoenfeld; Daniela Calina; Michael B Briggs; Demetrios A Spandidos; Aristidis Tsatsakis
Journal:  Toxicol Rep       Date:  2020-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.